Natural History in Children up to 10 Years With Moderate to Profound Hearing Loss Due to Mutations in GJB2 / OTOF Genes

Sensorineural Hearing Loss, Bilateral Clinical Trial

— Otoconex  

Official title:

Longitudinal Study of the Natural History of Two Autosomal Recessive Non Syndromic Deafness (DFNB1A and DFNB9) in Children up to 10 Years of Age

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05402813
• Other study ID #: SENS-NH01
• Status: Recruiting
• Start date: November 18, 2022
• Est. completion date: November 18, 2026

Study information

• Verified date: September 2023
• Source: Sensorion
• Contact: Judith LAREDO, PhD
• Phone: +33(0)663737108
• Email: judith.laredo[@]sensorion-pharma.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to follow the natural history of non-syndromic hearing loss caused by mutations in two genes (GJB2 or OTOF) in children up to 10 years of age.

Description:

The study aims to:

• better describe the prevalence of cases of DFNB1A and DFNB9, including the type of mutations, and to assess the clinical course of the disease in children up to 10 years of age who have a moderate to profound deafness.

• better understand the audiological and genetic characteristics of the participants with congenital versus evolutive DFNB1A and DFNB9 deafness.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 180
• Est. completion date: November 18, 2026
• Est. primary completion date: November 18, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A to 10 Years

Eligibility

Main Inclusion Criteria:

Participants meeting all the following main inclusion criteria will be eligible to participate in the study:

• Aged = 10 years on the date of signed informed consent;

• With a diagnosis of non-syndromic, bilateral, moderate to profound, sensorineural hearing loss (according to the American Speech Language-Hearing Association);

• With documented genotyping results showing mutation(s) in GJB2 or OTOF genes;

• Written informed consent as required by local regulations.

• Either without Cochlear Implant, or with unilateral or bilateral Cochlear Implant(s)

Exclusion Criteria:

Participants presenting with any of the following main exclusion criteria will not be included in the study

• Other type of deafness, such as unilateral deafness, persistent conductive deafness, malformation syndrome, syndromic deafness, known familial deafness linked to mutations in other genes than OTOF or GJB2;

• Documented genotyping results showing pathogenic mutation(s) in other gene(s) than GJB2 or OTOF genes in the tested panel;

• Unable and/or unwilling to comply with all the protocol requirements and/or study procedures.

Related Conditions & MeSH terms

• Congenital Deafness
• Deafness
• Hearing Loss
• Hearing Loss, Bilateral
• Hearing Loss, Sensorineural
• Sensorineural Hearing Loss, Bilateral

Intervention

Other:
• Pure Tone Audiometry Assessment
Collection of Pure Tone Audiometry data performed in routine practice during study period
• Quality of Life Questionnaires
Collection of Quality of Life questionnaire's answers during study period

Locations

Country	Name	City	State
France	Necker Hospital	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Sensorion

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Audiological characteristics	Pure Tone Audiometry, thresholds on 500, 1000, 2000, 4000 Hz Speech audiometry	Up to 2 years
Primary	Electrophysiological characteristics: ABR	Auditory Brainstem Response, thresholds	Up to 2 years
Primary	Electrophysiological characteristics: OAE	Otoacoustic Emissions thresholds	Up to 2 years
Secondary	Genotypic and phenotypic characterisation	Genotypic and phenotypic characterisation of the population will be assessed in Cohort 1a.; Frequency of autosomal recessive 1 and 9 deafness (GJB2 and OTOF genes) and type of mutations will be evaluated among the screened population of male and female children aged = 10 years, with a diagnosis of bilateral moderate to profound, sensorineural, non-syndromic hearing loss.	1 Day
Secondary	Hearing-related Quality of Life questionnaire	The Hearing Environments And Reflection on Quality of Life (HEAR-QL) measurement questionnaires will be used to assess the quality of life of children.; Depending on child's age, the HEAR-QL questionnaires will be completed either by parents/caregivers (child aged 2 to 6 years) either by the child (child aged 7 to 12 years).; The items of the questionnaires are focused on situations affecting interactions with family and friends, participation in social and school activities, and impact of Hearing Loss on the child's emotional well being.; Children/parents will be asked to rate how frequently each item was a problem for them/child in the past month using the following response choices: "never" (1), "almost never" (2), "sometimes" (3), "often" (4), or "Almost always" (5). Scores are transformed with 1=100, 2=75, 3=50, 4=25, and 5=0 points. Higher scores indicate higher perceived Quality Of Life.	Up to 2 years